ABSTRACT
Conventional collection, preservation, and retrieval of nucleic acid specimens, particularly unstable RNA, require costly cold-chain infrastructure and rely on inefficient robotic sample handling, hindering downstream analyses. These generate critical bottlenecks for global pathogen surveillance and genomic biobanking efforts, prohibiting large-scale nucleic acid sample collection and analyses that are needed to empower pathogen tracing, as well as rare disease diagnostics1. Here, we introduce a scalable nucleic acid storage system that enables rapid and precise retrieval on pooled nucleic acid samples—stored at room-temperature with minimal physical footprint2,3—using versatile database-like queries on barcoded, encapsulated samples. Queries can incorporate numerical ranges, categorical filters, and combinations thereof, which is a significant advancement beyond previous demonstrations limited to single-sample retrieval or Boolean classifiers. We apply our system to a pool of ninety-six mock SARS-CoV-2 genomic samples identified with theoretical patient data including patient age, geographic location, and diagnostic state, allowing rapid, multiplexed nucleic acid sample retrieval in a scalable manner to empower genomic analyses. By avoiding expensive and cumbersome freezer storage and retrieval systems, our approach in principle scales to millions of samples without loss of fidelity or throughput, thereby supporting the development of large-scale pathogen and genomic repositories in under-resourced or isolated regions of the US and worldwide.
Competing Interest Statement
The Massachusetts Institute of Technology has filed a patent related to this work on behalf of the authors. J.L.B. and M.B. are co-founders and equity shareholders of Cache DNA, Inc. (Cache). J.L.B. is an employee of Cache and an independent contractor of OpenAI. D.K.R. was an intern at Cache for the period of this work.
Funding Statement
M.B. and J.D.B. were supported by the Office of Naval Research (N00014-21-1-4013), the Army Research Office (ICB Subaward KK1954), and the National Science Foundation (CBET-1729397, OAC-1940231, and CCF-1956054). Additional funding to J.D.B. was provided through a National Science Foundation Graduate Research Fellowship (Grant No. 1122374). J.L.B. acknowledges support in part by the National Science Foundation SBIR Phase I 2136447, UCSF Parnassus Flow CoLab RRID:SCR_018206, DRC Center Grant NIH P30 DK063720, UCSF Center for Advanced Technology at Mission Bay, and Illumina. This research was also supported by a core center grant from the National Institute of Environmental Health Sciences, National Institutes of Health (P30-ES002109). We thank G. Paradis, M. Jennings, and M. Griffin of the Flow Cytometry Core at the Koch Institute at the Massachusetts Institute of Technology (MIT) for flow sorting assistance. We thank G. Tikhorimov for providing access to a Beckman Coulter Labcyte Echo 550.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
De-identified clinical samples were sourced from Delaware Diagnostic Labs. The MIT Committee on the Use of Humans as Experimental Subjects determined that IRB approval was not required for this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Abstract and introduction were edited to improve the clarity of the paper. Added clinical data.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
